School of Life Sciences, University of Technology Sydney, Broadway, NSW, 2007, Australia.
Guangdong Online Hospital, Guangdong Second Provincial People's Hospital, Guangzhou, 510317, PR China.
Biomed Pharmacother. 2019 Sep;117:109042. doi: 10.1016/j.biopha.2019.109042. Epub 2019 Jun 19.
Scutellarein (Sc), a natural compound and an active ingredient of Erigeron breviscapus (vant.), shows anti-inflammatory and antioxidant properties and has the potential for obesity treatment. However, no previous in vivo study has been conducted to assess the role of Sc in obesity. This study investigated the effects of Sc on obesity and associated hyperlipidemia and fatty liver and explores the underlying mechanisms of action in a mouse model.
The study was conducted using a well-established mouse model of obesity induced by high-fat diet (HFD) feeding. Anti-obesity effects were assessed using body weight, abdominal circumference, white adipose tissue, adiposity index, and fatty liver index. Lipid lowering and liver protective effects were examined by blood sample analysis. Lipid dystopia deposition was confirmed by liver pathological sections. The signaling pathways of lipid metabolism and cytokine/inflammatory mediator were evaluated using Real-Time PCR and Western blot.
Central obesity, dyslipidemia, inflammation, and hepatic steatosis were developed in mice fed with HFD. Administration of Sc at a dose of 50 mg/kg for 16 weeks effectively attenuated all obesity indicators tested. Further studies revealed the antagonistic effect of Sc on hyperlipidemia was a result of the repression of the lipid synthesis pathway, de novo pathway, HMGCR, promoting fatty acid oxidation (PPARα, CPT-1a) and increased cholesterol output (PPARγ-LXRα-ABCA1). The anti-inflammatory effect was attributed to blocking the expression of inflammatory genes, including TNF-α, IL-6, NF-κB.
These results suggest that Sc possesses important novel anti-obesity effects accompanying lipid lowering and anti-inflammation-based liver protective effects. These favorable effects are causally associated with the suppression of gene expression of inflammatory cytokines and fine regulation of genes responsible for energy metabolism. Our results advance the understanding of the pharmacological actions of Sc, and provides a role for Sc in effective management of obesity.
野黄芩苷(Sc)是一种天然化合物,也是灯盏花素(vant.)的一种活性成分,具有抗炎和抗氧化特性,并且具有治疗肥胖的潜力。然而,以前没有进行过体内研究来评估 Sc 在肥胖中的作用。本研究旨在评估 Sc 对肥胖及其相关高脂血症和脂肪肝的作用,并在小鼠模型中探讨其作用机制。
本研究使用高脂肪饮食(HFD)喂养诱导的肥胖小鼠模型进行。通过体重、腹围、白色脂肪组织、肥胖指数和脂肪肝指数评估抗肥胖作用。通过血液样本分析评估降脂和保肝作用。通过肝脏病理切片确认脂质异位沉积。使用实时 PCR 和 Western blot 评估脂质代谢和细胞因子/炎症介质的信号通路。
HFD 喂养的小鼠出现中心性肥胖、血脂异常、炎症和肝脂肪变性。Sc 以 50mg/kg 的剂量给药 16 周可有效减轻所有肥胖指标。进一步的研究表明,Sc 对高脂血症的拮抗作用是由于抑制脂质合成途径、从头途径、HMGCR,促进脂肪酸氧化(PPARα、CPT-1a)和增加胆固醇输出(PPARγ-LXRα-ABCA1)所致。抗炎作用归因于阻断炎症基因的表达,包括 TNF-α、IL-6、NF-κB。
这些结果表明,Sc 具有重要的新型抗肥胖作用,伴随降脂和抗炎性肝保护作用。这些有利影响与炎症细胞因子的基因表达抑制和能量代谢相关基因的精细调节有关。我们的结果加深了对 Sc 药理作用的理解,并为 Sc 在肥胖症的有效管理中提供了作用机制。